Sách hướng dẫn người chăm sóc để giúp đỡ người thân yêu mắc bệnh tâm thần phân liệt
Tham khảo tài liệu 'sách hướng dẫn người chăm sóc để giúp đỡ người thân yêu mắc bệnh tâm thần phân liệt', kỹ năng mềm, kỹ năng giao tiếp phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả
Sách hướng dẫn
người chăm sóc để giúp
đỡ người thân yêu mắc
bệnh tâm thần phân liệt
Để biết thêm thông tin về
RISPERDAL CONSTA, hãy
nói chuyện với bác sĩ hoặc
ghé thăm
www.risperdalconsta.com.
Hãy đọc thông tin quan
trọng về sản phầm được
đính kèm.
Khi người thân yêu của quí vị bị tâm
thần phân liệt Tìm hiểu về chứng tâm thần phân liệt
Sự giúp đỡ bắt đầu với niềm hy vọng Tâm thần phân liệt là gì?
Nếu người thân của quí vị bị tâm thần phân liệt, họ không Tâm thần phân liệt là một dạng rối loạn não. Chứng bệnh này
hề cô đơn. Mỗi năm có hơn 2 triệu người Mỹ bị bệnh này. đôi khi làm con người gặp rắc rối về chức năng trong cuộc sống
hàng ngày. Nghiên cứu cho thấy chứng tâm thần phân liệt có thể
Hiện giờ chưa có cách điều trị. Nhưng có hy vọng.
là do mất cân bằng hóa chất trong não gây ra. Sự mất cân bằng
này có thể tạo ra quá nhiều thông điệp lẫn lộn với nhau và sinh
Tập sách nhỏ này sẽ giúp quí vị giải đáp những thắc mắc
ra các triệu chứng.
về phương pháp điều trị bằng thuốc RISPERDAL CONSTA.
Ai mắc chứng tâm thần phân liệt?
Người ta không biết tại sao căn bệnh này lại xảy ra ở người này
mà không xảy ra ở người khác. Khả năng mắc chứng tâm thần
phân liệt tương đương nhau ở nam giới và nữ giới. Nam giới
thường bắt đầu có triệu chứng từ cuối những năm thiếu niên cho
đến đầu những năm 20 tuổi. Nữ giới thường bắt đầu có các triệu
chứng ở độ tuổi cuối những năm 20 và đầu những năm 30 tuổi.
Chỉ bác sỹ mới có thể chẩn đoán chính xác chứng tâm thần
phân liệt.
Trong cuốn sách nhỏ này là những lời trích dẫn từ những người mắc bệnh tâm
thần phân liệt đang được điều trị bằng thuốc tiêm có tác dụng lâu dài và từ
những người chăm sóc họ. Mặc dù có nhiều ví dụ về những phương pháp điều
trị thành công, kết quả của từng cá nhân có thể khác nhau.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Các triệu chứng của tâm thần phân
liệt là gì?
Những người bị tâm thần phân liệt có thể có những loại Các triệu chứng âm tính gồm:
triệu chứng khác nhau. Loại phổ biến nhất • Có ít cảm xúc hay các cảm giác không phù hợp trong một
số tình huống
là các triệu chứng dương tính và âm tính.
• Cảm xúc lạc lõng với những người khác
Dương tính nghĩa là thể hiện quá mức các triệu chứng hơn
• Có lúc gặp khó khăn trong giao tiếp ngôn ngữ với người
bình thường. Âm tính nghĩa là không khác
có những hành vi hoặc cảm xúc trong sinh hoạt
• Mất hứng thú với công việc hàng ngày
bình thường.
Các triệu chứng dương tính gồm:
• Tin vào những điều mà đa số những người khác không
nghĩ là thật hoặc đúng
• Nhìn và nghe thấy những điều mà những người khác
không thấy
• Cảm thấy lo lắng hoặc sợ hãi “Tôi đã phải nhắc
• Gặp khó khăn khi cần tập trung nó uống thuốc”.
Chị của David
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Các loại thuốc giúp đem lại hy vọng
Điều trị tâm thần phân liệt như thế nào? Tần suất sử dụng các loại thuốc
Hiện nay chưa có thuốc điều trị tâm thần phân liệt. khác nhau
Nhưng nghiên cứu đã dẫn đến việc phát triển các loại Thuốc chống loạn thần dùng cho tâm thần phân liệt được sử dụng
thuốc sử dụng kết hợp với một phác đồ điều trị hoàn chỉnh, theo 2 cách:
có giúp người thân yêu của quí vị kiểm soát được các triệu • Thuốc uống hàng ngày
chứng tâm thần phân liệt. — Thuốc uống qua đường miệng. Thường uống một hoặc hai lần
một ngày
Các bệnh nhân dùng nhiều loại thuốc
• Thuốc tiêm có tác dụng lâu dài (LAI)
khác nhau.
— Thuốc tiêm ở lại trong cơ thể một thời gian dài.
Các loại thuốc điều trị tâm thần phân liệt gọi là thuốc chống Điều này có nghĩa là số lần tiêm sẽ thưa hơn
loạn thần. Người ta chưa biết chính xác những loại thuốc
này hoạt động như thế nào. Nhưng những loại thuốc này
được cho là giúp lấy lại cân bằng các hóa chất trong não.
Theo cách này, các thông điệp không bị lẫn lộn. “Gia đình [bệnh nhân của tôi] rất hào
hứng khi biết có một loại thuốc tiêm có
Các loại thuốc chống loạn thần cũ hay thông thường đã
tác dụng lâu dài mà có thể giúp đề cập
được sử dụng trên 50 năm. Những loại thuốc này kiểm soát
vấn đề tuân thủ bằng cách cho tôi biết
các triệu chứng tâm thần phân liệt dương tính.
khi nào bệnh nhân bỏ một liều thuốc”.
Chuyên gia về tâm thần học
Những loại thuốc chống loạn thần mới, hay không điển hình
đã có trong 15 năm qua. Những loại thuốc này được gọi là
không điển hình do chúng khác với các loại thuốc chống
loạn thần truyền thống.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Tìm hiểu về liệu pháp tiêm tác dụng
lâu dài
Tại sao sử dụng thuốc LAI là đúng đắn cho Điều gì làm bệnh nhân và người chăm sóc
người thân yêu của quí vị thích liệu pháp thuốc LAI
Các thuốc LAI giải phóng lượng thuốc chống loạn thần một Cho tới gần đây, quí vị có thể không biết rằng liệu pháp
cách chậm và đều đặn vào cơ thể. Mỗi lần tiêm đưa vào thuốc LAI là một lựa chọn cho người thân yêu của mình.
lượng thuốc có tác dụng cả ngày và đêm trong vài tuần Thực tế là khi các bệnh nhân và người chăm sóc của họ
lễ. Kết quả là không cần phải sử dụng thuốc hàng ngày. được biết về liệu pháp thuốc LAI, họ thường có ý muốn
Thuốc LAI cũng cho phép quí vị và nhóm điều trị biết thử. Điều làm bệnh nhân và người chăm sóc thích liệu
và can thiệp nếu người thân yêu của quí vị bỏ lỡ một liều. pháp thuốc LAI là:
• Không cần phải lo lắng về người thân yêu của quí vị nếu
họ lỡ quên thuốc hàng ngày về bệnh tâm thần phân liệt
• Điều này có nghĩa là mỗi ngày bớt được việc uống một
viên thuốc
• Tâm trí của quí vị và người thân yêu của quí vị sẽ bình
thản hơn khi biết anh ấy hoặc cô ấy đã có thuốc cho cả
ngày hôm đó
• Không ai phải lo lắng về việc vô tình uống thuốc quá liều
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Thuốc LAI có thể có ích cho người thân
yêu của quí vị không?
Thuốc LAI được sử dụng như thế nào Hãy hoàn thành bản liệt kê kiểm tra sau đây. Nếu câu trả lời của quí
Các bác sỹ và y tá sử dụng thuốc LAI giống như nhiều loại vị là có cho bất cứ tuyên bố nào, hãy nói chuyện với bác sĩ. Thuốc
thuốc khác. Thuốc được tiêm vào cơ thể những người bị LAI có thể là một lựa chọn tốt cho người thân yêu của quí vị.
tâm thần phân liệt. Hầu hết các mũi tiêm nằm trên phần cơ
Tôi muốn con cái, cha mẹ, vợ chồng, anh chị em, người thân,
lớn trên cơ thể như:
bạn bè của tôi:
• Mông (cơ mông)
• Vai (cơ đen ta) Uống thuốc tâm thần phân liệt CÓ KHÔNG
ít thường xuyên hơn
Khi người thân yêu của quí vị được tiêm, anh ấy hoặc
cô ấy có thể cảm thấy hơi khó chịu.
Thử một thứ khác mà có thể giúp CÓ KHÔNG
kiểm soát các triệu chứng của họ
Mỗi người có mức độ chịu đau khác nhau. Việc họ cảm
thấy như thế nào trong lúc tiêm là vấn đề cá nhân.
Hãy thường xuyên liên lạc với CÓ KHÔNG
nhóm điều trị
Tương tự, đừng lo lắng nếu người thân yêu của quí vị cảm
thấy ngượng ngùng khi bị tiêm. Y tá hoặc bác sỹ sẽ giúp
người thân yêu của quí vị cảm thấy thoải mái hơn. Trong
nhiều trường hợp, họ sẽ được yêu cầu để hở chỉ một phần
da nhỏ. Thông thường không cần cởi quần áo trước khi
tiêm. Hãy nhớ, việc tiêm sẽ nhanh chóng qua đi.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
10 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
RISPERDAL CONSTA—thuốc
LAI có thể mang lại hi vọng cho
nhiều người
Bác sỹ đã chỉ định thuốc RISPERDAL CONSTA cho người • Tham gia các hoạt động có ý nghĩa như hòa mình với bạn bè và gia
đình hoặc tập thể dục
thân yêu của quí vị để giúp kiểm soát các triệu chứng tâm
thần phân liệt. RISPERDAL CONSTA đã giúp những người Khi người thân của quí vị được tiêm thuốc RISPERDAL CONSTA theo
bị tâm thần phân liệt ở hơn 50 nước trên thế giới. Một lần chỉ dẫn của bác sỹ như một phần của toàn bộ liệu pháp, có nhiều lý do
tiêm thuốc RISPERDAL CONSTA có thể giúp kiểm soát các để hy vọng rằng người thân yêu của quí vị có thể làm được nhiều việc
triệu chứng tâm thần phân liệt trong 2 tuần. Khả năng kiểm hơn anh ấy hoặc cô ấy muốn.
soát triệu chứng hiệu quả của nó đem lại sự nhẹ nhõm giúp
người thân của quí vị trở lại là chính mình. Tiêm thuốc RISPERDAL CONSTA như thế nào?
RISPERDAL CONSTA được tiêm vào phía trên mông bởi một chuyên gia
Một số mục tiêu có thể cho quí vị và người chăm sóc y tế 2 tuần một lần. Người thân yêu của quí vị có thể chỉ cần hạ
thân yêu của quí vị thấp cạp quần xuống một lúc trong lúc tiêm.
Các thuốc LAI như RISPERDAL CONSTA có thể làm giảm
những triệu chứng của tâm thần phân liệt. Khi người thân Trong suốt 3 tuần đầu điều trị bằng RISPERDAL CONSTA, bác sĩ có
yêu của quí vị cảm thấy tốt hơn, anh ấy hay cô ấy có thể: thể kê thuốc uống chữa bệnh tâm thần cùng với RISPERDAL CONSTA.
Thông thường chỉ cần dùng loại thuốc uống này trong thời gian đầu
• Quay lại các hoạt động hàng ngày như mua sắm điều trị.
và nấu nướng
• Sắp đặt và làm việc theo các mục tiêu cá nhân như:
— Quay lại làm việc
— Đi học trở lại
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
1 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Hãy nhớ, quí vị có sự hỗ trợ từ nhóm điều
trị của mình
Trong khi người thân yêu của quí vị đang điều trị bằng
thuốc RISPERDAL CONSTA, anh ấy hoặc cô ấy sẽ tới gặp
bác sỹ 2 tuần một lần để tiêm. Nhóm điều trị sẽ ở đó để
giúp đỡ cả hai—từng bước một.
Họ sẽ giúp quí vị theo dõi những triệu chứng và tiến triển
điều trị của người thân yêu của quí vị. Họ sẽ lắng nghe “Trước đây, Manuel không uống
những lo lắng và trả lời bất kỳ câu hỏi nào của quí vị. Quí vị thuốc hoặc quên không uống
có thể làm việc cùng nhóm điều trị để đảm bảo rằng người thuốc…nhưng bây giờ…thuốc
thân yêu của mình không bỏ lỡ buổi hẹn tiêm nào;
luôn có trong cơ thể của
nó và thuốc thật sự đang có tác
theo cách đó, thuốc được tiêm đúng hẹn và duy trì liên tục
dụng tốt”.
trong cơ thể.
Mẹ của Manuel
Các thành viên của nhóm điều trị gồm:
• Quí vị và người thân yêu của • Các bác sĩ
mình
• Các y tá xã hội • Người làm công tác
• Người quản lý ca bệnh • Các nhà tâm lý học
• Các tư vấn viên gia đình và • Các thành viên trong
ngang hàng bạn bè
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
1 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Những câu hỏi thường gặp
Liệu người thân yêu của có có bị tác Những thông tin an toàn khác nào cần
dụng phụ khi dùng thuốc RISPERDAL xem xét?
CONSTA không? Những bệnh nhân lớn tuổi bị rối loạn tâm thần có liên quan
Một số người gặp tác dụng phụ. Nói chuyện với nhóm điều đến mất trí nhớ được điều trị bằng các thuốc chống loạn
trị của quí vị về những tác dụng phụ cụ thể của bất kỳ loại thần không điển hình có nguy cơ tử vong cao hơn so với
thuốc nào mà người thân yêu của quí vị đang dùng. Khi quí dùng thuốc trấn an. RISPERDAL CONSTA (risperidone)
vị nói chuyện một cách cởi mở, nhóm điều trị có thể: không được phép sử dụng trong điều trị những bệnh nhân
bị rối loạn tâm thần có liên quan đến mất trí nhớ.
• Làm việc với quí vị để giúp kiểm soát các tác dụng phụ
Các nghiên cứu cho thấy một nguy cơ ngày càng tăng là các
• Đảm bảo rằng người thân yêu của quí vị đang dùng loại
thuốc hoạt động tốt và có lợi ích điều trị cao nhất tác dụng phụ liên quan đến tăng đường huyết, đôi khi dẫn đến
tử vong ở những bệnh nhân được điều trị loại thuốc này,
Trong một nghiên cứu về những người sử dụng thuốc
gồm có RISPERDAL CONSTA. Một số người có thể cần xét
RISPERDAL CONSTA, các tác dụng phụ thường gặp nhất
nghiệm đường huyết định kỳ.
trong điều trị tâm thần phân liệt là buồn ngủ, bồn chồn,
rùng mình và căng cứng cơ, nôn nao ở dạ dày, táo bón, Có thể quí vị đã nghe nói đến thuật ngữ “loạn vận động muộn”.
khô miệng, cảm giác mệt mỏi, và tăng cân. Đó là những cử động giật cơ mặt hoặc cơ thể chậm, không thể
kiểm soát và dai dẳng, có thể do tất cả các thuốc loại này gây
ra. Nếu quí vị để ý thấy những triệu chứng này, hãy nói chuyện
với bác sỹ.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
1 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Một tác dụng phụ hiếm gặp nhưng nghiêm trọng đã gặp Hãy thông báo cho bác sỹ nếu người đang điều trị có thai hoặc
với loại thuốc này, trong đó có RISPERDAL CONSTA, có kế hoạch mang thai trong khi dùng thuốc RISPERDAL
được biết như là NMS, hoặc hội chứng an thần ác tính. CONSTA. Không cho con bú trong khi dùng thuốc
NMS có đặc điểm cứng cơ, sốt và có thể rất nghiêm trọng. RISPERDAL CONSTA.
RISPERDAL CONSTA cần được sử dụng thận trọng RISPERDAL CONSTA có thể ảnh hưởng đến sự tỉnh táo hoặc
ở người bị động kinh, hay có tiền sử bị động kinh, hoặc có khả năng lái xe; do đó, người đang điều trị không nên lái
những tình trạng làm tăng nguy cơ mắc bệnh động kinh. xe hoặc vận hành máy móc trước khi nói chuyện với bác sỹ.
RISPERDAL CONSTA và những thuốc cùng loại có thể làm RISPERDAL CONSTA có thể ảnh hưởng đến sự tỉnh táo
tăng mức hoocmôn trong máu được biết như là prolactin, và kỹ năng lái mô-tô; hãy thận trọng cho đến khi tác dụng của
gây ra tình trạng rối loạn nội tiết tố chất prolactin. RISPERDAL CONSTA được biết đến.
Prolactin trong máu liên tục tăng nếu tiếp tục sử dụng
Tránh dùng các loại nước uống có cồn trong khi dùng thuốc
thuốc. Một số tác dụng phụ đã thấy được với những loại
RISPERDAL CONSTA.
thuốc này gồm có mất kinh; vú sinh ra sữa; vú phát triển
ở nam giới; và không thể cường dương. Mối liên hệ giữa Một số loại thuốc có tương tác với RISPERDAL CONSTA.
mức prolactin và các tác dụng phụ vẫn là điều bí ẩn. Hãy thông tin với chuyên gia y tế của quí vị về bất kỳ loại thuốc
hoặc chất bổ sung nào mà người đang điều trị sử dụng.
Một số người sử dụng RISPERDAL CONSTA có thể cảm
thấy chóng mặt hoặc mê sảng khi đứng hoặc ngồi dậy quá Nếu quí vị có bất kỳ câu hỏi nào về RISPERDAL CONSTA hoặc
đột ngột. về liệu pháp của người thân yêu, hãy nói chuyện với bác sỹ
của quí vị.
Khi đứng hoặc ngồi dậy từ từ và theo chỉ định liều lượng
của bác sỹ, tác dụng phụ này có thể giảm dần hoặc biến
mất theo thời gian.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
1 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Liệu tiêm có đau không? Bảo hiểm y tế có thanh toán cho thuốc
Trong một cuộc thử nghiệm lâm sàng, người sử dụng RISPERDAL CONSTA?
RISPERDAL CONSTA nói rằng họ cảm thấy hơi đau với Hầu hết các cơ quan bảo hiểm y tế đều thanh toán chi phí
lần tiêm đầu tiên. Những mũi tiêm sau càng đỡ đau hơn. thuốc RISPERDAL CONSTA.
Tôi còn có thể làm gì để giúp đỡ người Janssen, L.P., công ty sản xuất thuốc RISPERDAL CONSTA,
thân yêu? có thể giúp bệnh nhân khó có khả năng thanh toán cho việc
Quí vị có thể đóng vai trò quan trọng trong quá trình điều trị điều trị của mình. Các bệnh nhân có chi phí y tế cao và các
cho người thân yêu của mình. Một số việc quí vị có thể làm bệnh nhân không được thanh toán thuốc bán theo toa có thể
như sau: đủ điều kiện để nhận sự trợ giúp này. Để biết thêm thông tin
• Khuyến khích và động viên về Chương trình Hỗ trợ Bệnh nhân RISPERDAL CONSTA,
• Giúp người thân yêu của quí vị lấy thuốc như được bác hãy gọi số 1-800-652-6227, 9h sáng đến 5h chiề u , giờ ET,
sĩ của họ chỉ dẫn từ thứ Hai đến thứ Sáu.
• Hãy kiên nhẫn. Thuốc cần có thời gian để tích tụ ở mức
có tác dụng trong hệ thống
• Giữ liên lạc với nhóm điều trị
• Tìm hiểu cách giúp giảm căng thẳng ở người thân yêu
của quí vị
• Giúp người thân yêu thiết lập những mục tiêu thực
tế có thể đạt tới
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
0 Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Những nguồn cung cấp kiến thức
www.risperdalconsta.com www.mentalwellness.com
Trang web chính thức của RISPERDAL CONSTA Nguồn tài liệu trực tuyến về bệnh tâm thần phân liệt, rối loạn lưỡng
sẽ cho quí vị thông tin bổ sung quan trọng cực, và các thông tin về sức khỏe tâm thần chung.
về RISPERDAL CONSTA.
www.mentalhealthamerica.net
www.janssen.com 1-800-969-6642
Trang web này cung cấp những thông tin giá trị về những Hội Sức khỏe Tâm thần Mỹ, trước đây là Hiệp hội Sức khỏe Tâm
lựa chọn điều trị các bệnh tâm thần. thần Quốc gia, là tổ chức phi lợi nhuận lâu đời nhất và lớn nhất
về sức khỏe tâm thần và bệnh tâm thần.
www.nami.org
1-800-950-NAMI (6264) www.schizophrenia.com
Tổ chức Quốc gia về Bệnh Tâm thần (NAMI) hỗ trợ những Trang web này cung cấp thông tin, hỗ trợ và giáo dục về bệnh tâm
người bị bệnh tâm thần và gia đình, bạn bè của họ. thần phân liệt.
www.nimh.nih.gov www.strengthforcaring.com
1-866-615-6464 (đường dây miễn phí) Một trang web chứa thông tin giúp đỡ các thành viên gia đình đang
Viện Quốc gia Sức khỏe Tâm thần (NIMH) cung cấp thông chăm sóc người thân yêu bị bệnh tâm thần phân liệt và các bệnh tâm
tin về bệnh tâm thần và các lựa chọn điều trị. thần khác.
Để có thêm thông tin về RISPERDAL CONSTA, hãy nói với bác sĩ.
Vui lòng xem Thông tin Quan trọng về Sản phẩm đi kèm.
Để biết thêm thông tin
về RISPERDAL CONSTA,
hãy nói chuyện với bác sĩ
hoặc ghé thăm
www.risperdalconsta.com.
Hãy đọc thông tin quan
trọng về sản phầm được
© Janssen, L.P. 2008 Tháng Một 2008 01CS850BVN đính kèm.
other known enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital) with risperidone may cause similar
decreases in the combined plasma concentrations of risperidone and 9–hydroxyrisperidone, which could lead to
decreased efficacy of risperidone treatment (see PRECAUTIONS – Drug Interactions and DOSAGE AND
7519510
ADMINISTRATION – Co-Administration of RISPERDAL® CONSTA® with Certain Other Medications).
(0907)
01CS839 Fluoxetine (20 mg QD) and paroxetine (20 mg QD) have been shown to increase the plasma concentration of
risperidone 2.5-2.8 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of
9–hydroxyrisperidone. Paroxetine lowered the concentration of 9–hydroxyrisperidone by about 10% (see
Increased Mortality in Elderly Patients with Dementia–Related Psychosis PRECAUTIONS – Drug Interactions and DOSAGE AND ADMINISTRATION – Co-Administration of RISPERDAL®
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an CONSTA® with Certain Other Medications).
increased risk of death compared to placebo. Analyses of seventeen placebo controlled trials (modal Repeated oral doses of risperidone (3 mg BID) did not affect the exposure (AUC) or peak plasma concentrations (Cmax)
duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between
1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10 week controlled of lithium (n=13) (see PRECAUTIONS – Drug Interactions).
trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the Repeated oral doses of risperidone (4 mg QD) did not affect the pre-dose or average plasma concentrations and
placebo group. Although the causes of death were varied, most of the deaths appeared to be either exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a
cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. RISPERDAL® 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone (see
CONSTA® (risperidone) is not approved for the treatment of patients with Dementia-Related Psychosis. PRECAUTIONS – Drug Interactions).
There were no significant interactions between oral risperidone (1 mg QD) and erythromycin (500 mg QID) (see
DESCRIPTION PRECAUTIONS – Drug Interactions).
RISPERDAL® (risperidone) is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. The Cimetidine and ranitidine increased the bioavailability of risperidone by 64% and 26%, respectively. However, cimetidine
chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H- did not affect the AUC of the active moiety, whereas ranitidine increased the AUC of the active moiety by 20%.
pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C23H27FN4O2 and its molecular weight is 410.49. The structural Amitriptyline did not affect the pharmacokinetics of risperidone or the active moiety.
formula is: In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine,
which are metabolized by CYP 2D6.
RISPERDAL® (0.25 mg BID) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
Excretion
Risperidone and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by
a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male
volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces.
The apparent half-life of risperidone plus 9–hydroxyrisperidone following RISPERDAL® CONSTA® administration is 3 to
6 days, and is associated with a monoexponential decline in plasma concentrations. This half-life of 3-6 days is related
Risperidone is practically insoluble in water, freely soluble in methylene chloride, and soluble in methanol and 0.1 N HCl. to the erosion of the microspheres and subsequent absorption of risperidone. The clearance of risperidone and
risperidone plus 9–hydroxyrisperidone was 13.7 L/h and 5.0 L/h in extensive CYP 2D6 metabolizers, and 3.3 L/h and
RISPERDAL® CONSTA® (risperidone) Long-Acting Injection is a combination of extended release microspheres for
3.2 L/h in poor CYP 2D6 metabolizers, respectively. No accumulation of risperidone was observed during long-term use
injection and diluent for parenteral use.
(up to 12 months) in patients treated every 2 weeks with 25 mg or 50 mg RISPERDAL® CONSTA®. The elimination
The extended release microspheres formulation is a white to off-white, free-flowing powder that is available in dosage phase is complete approximately 7 to 8 weeks after the last injection.
strengths of 12.5, 25, 37.5, or 50 mg risperidone per vial. Risperidone is micro-encapsulated in 7525 polylactide-co-
Special Populations
glycolide (PLG) at a concentration of 381 mg risperidone per gram of microspheres.
Renal Impairment
The diluent for parenteral use is a clear, colorless solution. Composition of the diluent includes polysorbate 20, sodium In patients with moderate to severe renal disease treated with oral RISPERDAL®, clearance of the sum of risperidone and
carboxymethyl cellulose, disodium hydrogen phosphate dihydrate, citric acid anhydrous, sodium chloride, sodium its active metabolite decreased by 60% compared with young healthy subjects. Although patients with renal impairment
hydroxide, and water for injection. The microspheres are suspended in the diluent prior to injection. were not studied with RISPERDAL® CONSTA®, it is recommended that patients with renal impairment be carefully titrated
RISPERDAL® CONSTA® is provided as a dose pack, consisting of a vial containing the microspheres, a pre-filled on oral RISPERDAL® before treatment with RISPERDAL® CONSTA® is initiated at a dose of 25 mg. A lower initial dose of
syringe containing the diluent, a SmartSite® Needle-Free Vial Access Device, and one Needle-Pro® 20 G TW safety 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with renal impairment
needle. (see PRECAUTIONS – Use in Patients with Concomitant Illness and DOSAGE AND ADMINISTRATION – Dosage in
CLINICAL PHARMACOLOGY Special Populations).
Pharmacodynamics Hepatic Impairment
The mechanism of action of RISPERDAL® (risperidone), as with other drugs used to treat schizophrenia, is unknown. While the pharmacokinetics of oral RISPERDAL® in subjects with liver disease were comparable to those in young
However, it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the
dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism. Antagonism at receptors other than D2 and diminished concentration of both albumin and 1-acid glycoprotein. Although patients with hepatic impairment were not
5HT2 may explain some of the other effects of RISPERDAL®. studied with RISPERDAL® CONSTA®, it is recommended that patients with hepatic impairment be carefully titrated on
RISPERDAL® is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 oral RISPERDAL® before treatment with RISPERDAL® CONSTA® is initiated at a dose of 25 mg. A lower initial dose of
(5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. RISPERDAL® acts as an 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with hepatic impairment
antagonist at other receptors, but with lower potency. RISPERDAL® has low to moderate affinity (Ki of 47 to 253 nM) for (see PRECAUTIONS – Use in Patients with Concomitant Illness and DOSAGE AND ADMINISTRATION – Dosage in
the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and Special Populations).
haloperidol-sensitive sigma site, and no affinity (when tested at concentrations >10-5 M) for cholinergic muscarinic or ß1 Elderly
and ß2 adrenergic receptors. In an open-label trial, steady-state concentrations of risperidone plus 9–hydroxyrisperidone in otherwise healthy elderly
Pharmacokinetics patients (≥65 years old) treated with RISPERDAL® CONSTA® for up to 12 months fell within the range of values
Absorption observed in otherwise healthy nonelderly patients. Dosing recommendations are the same for otherwise healthy elderly
After a single intramuscular (gluteal) injection of RISPERDAL® CONSTA® (risperidone), there is a small initial release of patients and nonelderly patients (see DOSAGE AND ADMINISTRATION).
the drug (cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), The relevance of these findings to human risk is unknown.
and acute renal failure. Hyperprolactinemia
The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to As with other drugs that antagonize dopamine D2 receptors, risperidone elevates prolactin levels and the elevation
identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other
infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important antipsychotic agents. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin
considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male
central nervous system pathology. patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-
The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased
essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any bone density in both female and male subjects.
concomitant serious medical problems for which specific treatments are available. There is no general agreement about Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro,
specific pharmacological treatment regimens for uncomplicated NMS. a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected
If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy breast cancer. An increase in pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary
should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies
reported. conducted in mice and rats (see PRECAUTIONS – Carcinogenesis, Mutagenesis, Impairment of Fertility). Neither
clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration
Tardive Dyskinesia of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at
A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with this time.
antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially
elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, Potential for Cognitive and Motor Impairment
which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause Somnolence was reported by 5% of patients treated with RISPERDAL® CONSTA® in multiple-dose trials. Since
tardive dyskinesia is unknown. risperidone has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that treatment with RISPERDAL®
The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as CONSTA® does not affect them adversely.
the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.
However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Priapism
No cases of priapism have been reported in patients treated with RISPERDAL® CONSTA®. However, rare cases of
There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or priapism have been reported in patients treated with oral RISPERDAL®. While the relationship of these events to oral
completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially RISPERDAL® use has not been established, other drugs with alpha-adrenergic blocking effects have been reported to
suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect induce priapism, and it is possible that RISPERDAL® may share this capacity. Severe priapism may require surgical
that symptomatic suppression has upon the long-term course of the syndrome is unknown. intervention.
Given these considerations, RISPERDAL® CONSTA® should be prescribed in a manner that is most likely to minimize Thrombotic Thrombocytopenic Purpura (TTP)
the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who A single case of TTP was reported in a 28 year-old female patient receiving oral RISPERDAL® in a large, open
suffer from a chronic illness that: (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally premarketing experience (approximately 1300 patients). She experienced jaundice, fever, and bruising, but eventually
effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic recovered after receiving plasmapheresis. The relationship to RISPERDAL® therapy is unknown.
treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be
sought. The need for continued treatment should be reassessed periodically. Antiemetic Effect
Risperidone has an antiemetic effect in animals; this effect may also occur in humans, and may mask signs and
If signs and symptoms of tardive dyskinesia appear in a patient treated with RISPERDAL ® CONSTA ®, drug symptoms of overdosage with certain drugs or of conditions such as intestinal obstruction, Reye’s syndrome, and brain
discontinuation should be considered. However, some patients may require treatment with RISPERDAL® CONSTA® tumor.
despite the presence of the syndrome.
Body Temperature Regulation
Cerebrovascular Adverse Events, Including Stroke, in Elderly Patients with Dementia-Related Psychosis Disruption of body temperature regulation has been attributed to antipsychotic agents. Both hyperthermia and
Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients hypothermia have been reported in association with oral RISPERDAL® use. Caution is advised when prescribing
(mean age 85 years; range 73-97) in trials of oral risperidone in elderly patients with dementia-related psychosis. In RISPERDAL® CONSTA® for patients who will be exposed to temperature extremes.
placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated
with oral risperidone compared to patients treated with placebo. RISPERDAL® CONSTA® is not approved for the Suicide
treatment of patients with dementia-related psychosis. (See also Boxed WARNING, WARNINGS: Increased Mortality in The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should
Elderly Patients with Dementia-Related Psychosis.) accompany drug therapy. RISPERDAL® CONSTA® is to be administered by a health care professional (see DOSAGE
and ADMINISTRATION); therefore, suicide due to an overdose is unlikely.
Hyperglycemia and Diabetes Mellitus
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been Use in Patients with Concomitant Illness
reported in patients treated with atypical antipsychotics including RISPERDAL®. Assessment of the relationship between Clinical experience with RISPERDAL® CONSTA® in patients with certain concomitant systemic illnesses is limited.
atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of Patients with Parkinson's Disease or Dementia with Lewy Bodies who receive antipsychotics, including RISPERDAL®
diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general CONSTA®, are reported to have an increased sensitivity to antipsychotic medications. Manifestations of this increased
population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related sensitivity have been reported to include confusion, obtundation, postural instability with frequent falls, extrapyramidal
adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment- symptoms, and clinical features consistent with the neuroleptic malignant syndrome.
emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk Caution is advisable when using RISPERDAL® CONSTA® in patients with diseases or conditions that could affect
estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. metabolism or hemodynamic responses. RISPERDAL® CONSTA® has not been evaluated or used to any appreciable
Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses
monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family were excluded from clinical studies during the product’s premarket testing.
history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing Increased plasma concentrations of risperidone and 9–hydroxyrisperidone occur in patients with severe renal
at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should impairment (creatinine clearance RISPERDAL® CONSTA® may need to be adjusted. A dose increase, or additional oral RISPERDAL®, may need to be lactation at doses of 0.16-5 mg/kg or 0.1 to 3 times the oral MRHD on a mg/m2 basis. It is not known whether these
considered. On discontinuation of carbamazepine or other CYP 3A4 hepatic enzyme inducers, the dosage of deaths were due to a direct effect on the fetuses or pups or to effects on the dams.
RISPERDAL® CONSTA® should be re-evaluated and, if necessary, decreased. Patients may be placed on a lower dose There was no no-effect dose for increased rat pup mortality. In one peri/post-natal development study, there was an
of RISPERDAL® CONSTA® between 2 to 4 weeks before the planned discontinuation of carbamazepine or other CYP increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the oral MRHD on a mg/m2 basis. In a cross-fostering
3A4 enzyme inducers to adjust for the expected increase in plasma concentrations of risperidone plus study in Wistar rats, toxic effects on the fetus or pups, as evidenced by a decrease in the number of live pups and an
9–hydroxyrisperidone. For patients treated with the recommended dose of 25 mg RISPERDAL® CONSTA® and increase in the number of dead pups at birth (Day 0), and a decrease in birth weight in pups of drug-treated dams were
discontinuing from carbamazepine or other CYP 3A4 enzyme inducers, it is recommended to continue treatment with observed. In addition, there was an increase in deaths by Day 1 among pups of drug-treated dams, regardless of
the 25 mg dose unless clinical judgment necessitates lowering the RISPERDAL® CONSTA® dose to 12.5 mg or whether or not the pups were cross-fostered. Risperidone also appeared to impair maternal behavior in that pup body
necessitates interruption of RISPERDAL® CONSTA® treatment. (See also DOSAGE AND ADMINISTRATION.) The weight gain and survival (from Days 1 to 4 of lactation) were reduced in pups born to control but reared by drug-treated
efficacy of the 12.5 mg dose has not been investigated in clinical trials. dams. These effects were all noted at the one dose of risperidone tested, i.e., 5 mg/kg or 3 times the oral MRHD on a
Fluoxetine and Paroxetine mg/m2 basis.
Fluoxetine (20 mg QD) and paroxetine (20 mg QD), CYP 2D6 inhibitors, have been shown to increase the plasma No studies were conducted with RISPERDAL® CONSTA®.
concentration of risperidone 2.5-2.8 fold and 3-9 fold, respectively. Fluoxetine did not affect the plasma concentration of
9–hydroxyrisperidone. Paroxetine lowered the concentration of 9–hydroxyrisperidone by about 10%. When either Placental transfer of risperidone occurs in rat pups. There are no adequate and well-controlled studies in pregnant
concomitant fluoxetine or paroxetine is initiated or discontinued, the physician should re-evaluate the dose of women. However, there was one report of a case of agenesis of the corpus callosum in an infant exposed to risperidone
RISPERDAL® CONSTA®. When initiation of fluoxetine or paroxetine is considered, patients may be placed on a lower in utero. The causal relationship to oral RISPERDAL® therapy is unknown. Reversible extrapyramidal symptoms in the
dose of RISPERDAL® CONSTA® between 2 to 4 weeks before the planned start of fluoxetine or paroxetine therapy to neonate were observed following postmarketing use of risperidone during the last trimester of pregnancy.
adjust for the expected increase in plasma concentrations of risperidone. When fluoxetine or paroxetine is initiated in RISPERDAL® CONSTA® should be used during pregnancy only if the potential benefit justifies the potential risk to the
patients receiving the recommended dose of 25 mg RISPERDAL® CONSTA®, it is recommended to continue treatment fetus.
with the 25 mg dose unless clinical judgment necessitates lowering the RISPERDAL® CONSTA® dose to 12.5 mg or Labor and Delivery
necessitates interruption of RISPERDAL® CONSTA® treatment. When RISPERDAL® CONSTA® is initiated in patients The effect of RISPERDAL® CONSTA® on labor and delivery in humans is unknown.
already receiving fluoxetine or paroxetine, a starting dose of 12.5 mg can be considered. The efficacy of the 12.5 mg
dose has not been investigated in clinical trials. (See also DOSAGE AND ADMINISTRATION.) The effects of Nursing Mothers
discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone and In animal studies, risperidone and 9–hydroxyrisperidone are excreted in milk. Risperidone and 9–hydroxyrisperidone are
9–hydroxyrisperidone have not been studied. also excreted in human breast milk. Therefore, women should not breast-feed during treatment with RISPERDAL®
CONSTA® and for at least 12 weeks after the last injection.
Lithium
Repeated oral doses of risperidone (3 mg BID) did not affect the exposure (AUC) or peak plasma concentrations (Cmax) Pediatric Use
of lithium (n=13). RISPERDAL® CONSTA® has not been studied in children younger than 18 years old.
Valproate Geriatric Use
Repeated oral doses of risperidone (4 mg QD) did not affect the pre-dose or average plasma concentrations and In an open-label study, 57 clinically stable, elderly patients (≥65 years old) with schizophrenia or schizoaffective disorder
exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a received RISPERDAL® CONSTA® every 2 weeks for up to 12 months. In general, no differences in the tolerability of
20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone. RISPERDAL® CONSTA® were observed between otherwise healthy elderly and nonelderly patients. Therefore, dosing
recommendations for otherwise healthy elderly patients are the same as for nonelderly patients. Because elderly
Digoxin patients exhibit a greater tendency to orthostatic hypotension than nonelderly patients, elderly patients should be
RISPERDAL® (0.25 mg BID) did not show a clinically relevant effect on the pharmacokinetics of digoxin. instructed in nonpharmacologic interventions that help to reduce the occurrence of orthostatic hypotension (e.g., sitting
Drugs that Inhibit CYP 2D6 and Other CYP Isozymes on the edge of the bed for several minutes before attempting to stand in the morning and slowly rising from a seated
Risperidone is metabolized to 9–hydroxyrisperidone by CYP 2D6, an enzyme that is polymorphic in the population and position). In addition, monitoring of orthostatic vital signs should be considered in elderly patients for whom orthostatic
that can be inhibited by a variety of psychotropic and other drugs (see CLINICAL PHARMACOLOGY). Drug interactions hypotension is of concern (see CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND
that reduce the metabolism of risperidone to 9–hydroxyrisperidone would increase the plasma concentrations of ADMINISTRATION).
risperidone and lower the concentrations of 9–hydroxyrisperidone. Analysis of clinical studies involving a modest Concomitant use with Furosemide in Elderly Patients with Dementia-Related Psychosis
number of poor metabolizers (n 70 patients) does not suggest that poor and extensive metabolizers have different
In two of four placebo-controlled trials in elderly patients with dementia-related psychosis, a higher incidence of mortality
rates of adverse effects. No comparison of effectiveness in the two groups has been made.
was observed in patients treated with furosemide plus oral risperidone when compared to patients treated with oral
In vitro studies showed that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are risperidone alone or with oral placebo plus furosemide. No pathological mechanism has been identified to explain this
only weak inhibitors of risperidone metabolism. finding, and no consistent pattern for cause of death was observed. An increase of mortality in elderly patients with
There were no significant interactions between risperidone and erythromycin (see CLINICAL PHARMACOLOGY). dementia-related psychosis was seen with the use of oral risperidone regardless of concomitant use with furosemide.
Drugs Metabolized by CYP 2D6 RISPERDAL® CONSTA® is not approved for the treatment of patients with dementia-related psychosis. (See Boxed
In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, RISPERDAL® CONSTA® is WARNING,WARNINGS: Increased Mortality in Elderly Patients with Dementia-Related Psychosis.)
not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug ADVERSE REACTIONS
interaction studies, oral risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, Adverse findings were assessed by spontaneous reports of adverse events, laboratory tests, vital signs, body weight,
which are metabolized by CYP 2D6. and ECGs. Adverse events were classified using the World Health Organization preferred terms. Treatment-emergent
Carcinogenesis, Mutagenesis, Impairment of Fertility adverse events were defined as those events with an onset between the first dose and 49 days after the last dose.
Carcinogenesis - Oral The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course
Carcinogenicity studies were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at of usual medical practice where patient characteristics and other factors differ from those which prevailed in this clinical
doses of 0.63, 2.5, and 10 mg/kg for 18 months to mice and for 25 months to rats. These doses are equivalent to 2.4, 9.4, trial. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving
and 37.5 times the oral maximum recommended human dose (MRHD) for schizophrenia (16 mg/day) on a mg/kg basis, or different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some
0.2, 0.75, and 3 times the oral MRHD (mice) or 0.4, 1.5, and 6 times the oral MRHD (rats) on a mg/m2 basis. A maximum basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the
tolerated dose was not achieved in male mice. There was a significant increase in pituitary gland adenomas in female mice population studied.
at doses 0.75 and 3 times the oral MRHD on a mg/m2 basis. There was a significant increase in endocrine pancreatic Associated with Discontinuation of Treatment
adenomas in male rats at doses 1.5 and 6 times the oral MRHD on a mg/m2 basis. Mammary gland adenocarcinomas In the 12-week, placebo-controlled trial, the incidence of schizophrenic patients who discontinued treatment due to an
were significantly increased in female mice at all doses tested (0.2, 0.75, and 3 times the oral MRHD on a mg/m2 basis), in adverse event was lower with RISPERDAL® CONSTA® (11%; 22/202 patients) than with placebo (13%; 13/98 patients).
female rats at all doses tested (0.4, 1.5, and 6 times the oral MRHD on a mg/m2 basis), and in male rats at a dose 6 times
Incidence in Controlled Trials
the oral MRHD on a mg/m2 basis.
The incidence of adverse reactions in the placebo-controlled trial was based on 202 schizophrenic patients treated with
Carcinogenesis - IM 25 or 50 mg RISPERDAL® CONSTA® and 98 schizophrenic patients treated with placebo for up to 12 weeks.
RISPERDAL® CONSTA® was evaluated in a 24-month carcinogenicity study in which SPF Wistar rats were treated every
Commonly Observed Adverse Events in Controlled Clinical Trials
2 weeks with IM injections of either 5 mg/kg or 40 mg/kg of risperidone. These doses are 1 and 8 times the MRHD (50 mg)
Spontaneously reported, treatment-emergent adverse events with an incidence of 5% or greater in at least one of the
on a mg/m2 basis. A control group received injections of 0.9% NaCl, and a vehicle control group was injected with
RISPERDAL® CONSTA® groups (25 mg or 50 mg) and at least twice that of placebo were: somnolence, akathisia,
placebo microspheres. There was a significant increase in pituitary gland adenomas, endocrine pancreas adenomas,
parkinsonism, dyspepsia, constipation, dry mouth, fatigue, weight increase.
and adrenomedullary pheochromocytomas at 8 times the IM MRHD on a mg/m2 basis. The incidence of mammary
gland adenocarcinomas was significantly increased in female rats at both doses (1 and 8 times the IM MRHD on a Adverse Events Occurring at an Incidence of 2% or More in Patients Treated with RISPERDAL® CONSTA®:
mg/m2 basis). A significant increase in renal tubular tumors (adenoma, adenocarcinomas) was observed in male rats at Table 1 enumerates adverse events that occurred at an incidence of 2% or more, and were at least as frequent among
8 times the IM MRHD on a mg/m2 basis. Plasma exposures (AUC) in rats were 0.3 and 2 times (at 5 and 40 mg/kg, patients treated with 25 mg or 50 mg RISPERDAL® CONSTA® as patients treated with placebo in the 12-week, placebo-
respectively) the expected plasma exposure (AUC) at the IM MRHD. controlled trial. This table shows the percentage of patients in each dose group who spontaneously reported at least one
episode of an event at some time during double-blind treatment. All patients were titrated to a dose of 4 mg oral
Dopamine D2 receptor antagonists have been shown to chronically elevate prolactin levels in rodents. Serum prolactin
RISPERDAL® during a 1-week run-in period. Patients who received RISPERDAL® CONSTA® were given doses of oral
levels were not measured during the carcinogenicity studies of oral risperidone; however, measurements taken during
RISPERDAL® (2 mg for patients in the 25-mg group, and 4 mg for patients in the 50-mg group) during the 3 weeks after
subchronic toxicity studies showed that oral risperidone elevated serum prolactin levels 5- to 6-fold in mice and rats at the
the first injection to provide therapeutic levels until the main release phase of risperidone from the injection site had
same doses used in the oral carcinogenicity studies. Serum prolactin levels increased in a dose-dependent manner up to
begun. Patients who received placebo injections were given placebo tablets.
6- and 1.5-fold in male and female rats, respectively, at the end of the 24-month treatment with RISPERDAL® CONSTA®
every 2 weeks. Increases in the incidence of pituitary gland, endocrine pancreas, and mammary gland neoplasms have Table 1. Incidence (% of Patients) of Treatment-Emergent Adverse Events in a 12-Week,
been found in rodents after chronic administration of other antipsychotic drugs and may be prolactin-mediated. Placebo-Controlled Clinical Trial
The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown (see RISPERDAL® CONSTA®
PRECAUTIONS - Hyperprolactinemia).
WHO Body System Disorder/ 25 mg 50 mg Placebo
Mutagenesis
No evidence of mutagenic potential for oral risperidone was found in the in vitro Ames reverse mutation test, in vitro Preferred Term (N=99) (N=103) (N=98)
mouse lymphoma assay, in vitro rat hepatocyte DNA-repair assay, in vivo oral micronucleus test in mice, the sex-linked Psychiatric
recessive lethal test in Drosophila, or the in vitro chromosomal aberration test in human lymphocytes or in Chinese
hamster cells. Insomnia 16 13 14
Hallucination 7 6 5
In addition, no evidence of mutagenic potential was found in the in vitro Ames reverse mutation test for RISPERDAL® Somnolence 5 6 3
CONSTA®. Suicide attempt 1 4 3
Impairment of Fertility Abnormal thinking 0 3 2
Oral risperidone (0.16 to 5 mg/kg) was shown to impair mating, but not fertility, in Wistar rats in three reproductive Abnormal dreaming 2 0 0
studies (two mating and fertility studies and a multigenerational study) at doses 0.1 to 3 times the oral maximum Central & peripheral nervous system
recommended human dose (MRHD) (16 mg/day) on a mg/m2 basis. The effect appeared to be in females, since
impaired mating behavior was not noted in the mating and fertility study in which males only were treated. In a Headache 15 22 12
subchronic study in Beagle dogs in which oral risperidone was administered at doses of 0.31 to 5 mg/kg, sperm motility Dizziness 8 11 6
and concentration were decreased at doses 0.6 to 10 times the oral MRHD on a mg/m2 basis. Dose-related decreases Akathisia 2 9 4
were also noted in serum testosterone at the same doses. Serum testosterone and sperm values partially recovered, Parkinsonisma 4 10 3
but remained decreased after treatment was discontinued. No no-effect doses were noted in either rat or dog. Tremor 0 3 0
Hypoaesthesia 2 0 0
No mating and fertility studies were conducted with RISPERDAL® CONSTA®.
Gastrointestinal
Pregnancy
Pregnancy Category C Dyspepsia 7 7 2
The teratogenic potential of oral risperidone was studied in three embryofetal development studies in Sprague-Dawley Constipation 5 7 1
and Wistar rats (0.63-10 mg/kg or 0.4 to 6 times the oral maximum recommended human dose [MRHD] on a mg/m2 Mouth dry 0 7 1
basis) and in one embryofetal development study in New Zealand rabbits (0.31-5 mg/kg or 0.4 to 6 times the oral MRHD Toothache 1 3 0
on a mg/m2 basis). The incidence of malformations was not increased compared to control in offspring of rats or rabbits Saliva increased 6 2 1
given 0.4 to 6 times the oral MRHD on a mg/m2 basis. In three reproductive studies in rats (two peri/post-natal Tooth disorder 4 2 0
development studies and a multigenerational study), there was an increase in pup deaths during the first 4 days of Diarrhea 5 1 3
3
Table 1. Incidence (% of Patients) of Treatment-Emergent Adverse Events in a 12-Week, a
In the integrated database of multiple-dose studies (1499 patients with schizophrenia or schizoaffective disorder),
Placebo-Controlled Clinical Trial (continued) 9 patients (0.6%) treated with RISPERDAL® CONSTA® (all dosages combined) experienced an adverse event of
RISPERDAL® CONSTA® tardive dyskinesia.
WHO Body System Disorder/ 25 mg 50 mg Placebo Body as a Whole/General Disorders
Preferred Term (N=99) (N=103) (N=98) Frequent: back pain, chest pain, asthenia. Infrequent: malaise, choking.
Gastrointestinal Disorders
Body as a whole - general Frequent: nausea, vomiting, abdominal pain. Infrequent: gastritis, gastroesophageal reflux, flatulence, hemorrhoids,
Fatigue 3 7 0 melena, dysphagia, rectal hemorrhage, stomatitis, colitis, gastric ulcer, gingivitis, irritable bowel syndrome, ulcerative
Pain 10 3 4 stomatitis.
Peripheral edema 2 3 1 Respiratory System Disorders
Leg pain 4 1 1 Frequent: dyspnea. Infrequent: pneumonia, stridor, hemoptysis. Rare: pulmonary edema.
Fever 2 1 0
Syncope 2 0 0 Skin and Appendage Disorders
Frequent: rash. Infrequent: eczema, pruritus, erythematous rash, dermatitis, alopecia, seborrhea, photosensitivity
Respiratory system reaction, increased sweating.
Rhinitis 14 4 8 Metabolic and Nutritional Disorders
Coughing 5 2 4 Infrequent: hyperuricemia, hyperglycemia, hyperlipemia, hypokalemia, glycosuria, hypercholesterolemia, obesity,
Sinusitis 3 1 0 dehydration, diabetes mellitus, hyponatremia.
Upper respiratory tract infection 2 0 1
Musculo-Skeletal System Disorders
Metabolic & nutritional Frequent: arthralgia, skeletal pain. Infrequent: torticollis, arthrosis, muscle weakness, tendinitis, arthritis, arthropathy.
Weight increase 5 4 2 Heart Rate and Rhythm Disorders
Weight decrease 4 1 1 Frequent: tachycardia. Infrequent: bradycardia, AV block, palpitation, bundle branch block. Rare: T-wave inversion.
Cardiovascular Cardiovascular Disorders
Hypertension 3 3 2 Frequent: hypotension. Infrequent: postural hypotension.
Hearing & vestibular Urinary System Disorders
Ear disorder (NOS) 0 3 0 Frequent: urinary incontinence. Infrequent: hematuria, micturition frequency, renal pain, urinary retention.
Vision Vision Disorders
Infrequent: conjunctivitis, eye pain, abnormal accommodation.
Vision abnormal 2 3 0
Reproductive Disorders, Female
Skin & appendages Frequent: amenorrhea. Infrequent: nonpuerperal lactation, vaginitis, dysmenorrhea, breast pain, leukorrhea.
Acne 2 2 0 Resistance Mechanism Disorders
Skin dry 2 0 0 Infrequent: abscess.
Musculo-Skeletal Liver and Biliary System Disorders
Myalgia 4 2 1 Frequent: increased hepatic enzymes. Infrequent: hepatomegaly, increased SGPT. Rare: bilirubinemia, increased GGT,
a
hepatitis, hepatocellular damage, jaundice, fatty liver, increased SGOT.
Includes adverse events of bradykinesia, extrapyramidal disorder, and hypokinesia.
Reproductive Disorders, Male
Dose Dependency of Adverse Events Infrequent: ejaculation failure.
Extrapyramidal Symptoms:
Two methods were used to measure extrapyramidal symptoms (EPS) in the 12-week, placebo-controlled trial comparing Application Site Disorders
three doses of RISPERDAL® CONSTA® (25 mg, 50 mg, and 75 mg) with placebo, including: (1) the incidence of Frequent: injection site pain. Infrequent: injection site reaction.
spontaneous reports of EPS symptoms; and (2) the change from baseline to endpoint on the total score (sum of the Hearing and Vestibular Disorders
subscale scores for parkinsonism, dystonia, and dyskinesia) of the Extrapyramidal Symptom Rating Scale (ESRS). Infrequent: earache, deafness, hearing decreased.
As shown in Table 1, the overall incidence of EPS-related adverse events (akathisia, dystonia, parkinsonism, and Red Blood Cell Disorders
tremor) in patients treated with 25 mg RISPERDAL® CONSTA® was comparable to that of patients treated with placebo; Frequent: anemia.
the incidence of EPS-related adverse events was higher in patients treated with 50 mg RISPERDAL® CONSTA®. White Cell and Resistance Disorders
The median change from baseline to endpoint in total ESRS score showed no worsening in patients treated with RISPERDAL® Infrequent: lymphadenopathy, leucopenia, cervical lymphadenopathy. Rare: granulocytopenia, leukocytosis,
CONSTA® compared with patients treated with placebo: 0 (placebo group); -1 (25-mg group, significantly less than the lymphopenia.
placebo group); and 0 (50-mg group). Endocrine Disorders
Vital Sign Changes: Infrequent: hyperprolactinemia, gynecomastia, hypothyroidism.
RISPERDAL® is associated with orthostatic hypotension and tachycardia (see PRECAUTIONS). In the placebo- Platelet, Bleeding and Clotting Disorders
controlled trial, orthostatic hypotension was observed in 2% of patients treated with 25 mg or 50 mg RISPERDAL® Infrequent: purpura, epistaxis. Rare: pulmonary embolism, hematoma, thrombocytopenia.
CONSTA® (see PRECAUTIONS).
Myo-, Endo-, and Pericardial and Valve Disorders
Weight Changes: Infrequent: myocardial ischemia, angina pectoris, myocardial infarction.
In the 12-week, placebo-controlled trial, 9% of patients treated with RISPERDAL® CONSTA®, compared with 6% of
patients treated with placebo, experienced a weight gain of >7% of body weight at endpoint. Vascular (Extracardiac) Disorders
Infrequent: phlebitis. Rare: intermittent claudication, flushing, thrombophlebitis.
Laboratory Changes:
The percentage of patients treated with RISPERDAL® CONSTA® who experienced potentially important changes in Postintroduction Reports
routine serum chemistry, hematology, or urinalysis parameters was similar to or less than that of placebo patients. Adverse events reported since market introduction which were temporally (but not necessarily causally) related to oral
Additionally, no patients discontinued treatment due to changes in serum chemistry, hematology, or urinalysis parameters. RISPERDAL® therapy include the following: anaphylactic reaction, angioedema, apnea, atrial fibrillation, cerebrovascular
disorder, including cerebrovascular accident, diabetes mellitus aggravated, including diabetic ketoacidosis,
ECG Changes: hyperglycemia, intestinal obstruction, jaundice, mania, pancreatitis, Parkinson’s disease aggravated, pituitary
The electrocardiograms of 202 schizophrenic patients treated with 25 mg or 50 mg RISPERDAL® CONSTA® and 98 adenomas, pulmonary embolism, and QT prolongation. There have been rare reports of sudden death and/or
schizophrenic patients treated with placebo in a 12-week, double-blind, placebo-controlled trial were evaluated. cardiopulmonary arrest in patients receiving oral RISPERDAL®. A causal relationship with oral RISPERDAL® has not
Compared with placebo, there were no statistically significant differences in QTc intervals (using Fridericia’s and linear been established. It is important to note that sudden and unexpected death may occur in psychotic patients whether
correction factors) during treatment with RISPERDAL® CONSTA®. they remain untreated or whether they are treated with other antipsychotic drugs.
Between-group comparisons for pooled placebo-controlled trials with oral RISPERDAL® revealed no statistically Retinal artery occlusion after injection of RISPERDAL® CONSTA® has been reported during postmarketing surveillance.
significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including This has been reported in the presence of abnormal arteriovenous anastomosis.
QT, QTc, and PR intervals, and heart rate. When all oral RISPERDAL® doses were pooled from randomized controlled
trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for DRUG ABUSE AND DEPENDENCE
placebo patients. In short-term schizophrenia trials, higher doses of oral risperidone (8-16 mg/day) were associated with Controlled Substance Class
a higher mean increase in heart rate compared to placebo (4-6 beats per minute). RISPERDAL® CONSTA® (risperidone) is not a controlled substance.
Pain Assessment and Local Injection Site Reactions: Physical and Psychological Dependence
The mean intensity of injection pain reported by patients using a visual analog scale (0 = no pain to 100 = unbearably RISPERDAL® CONSTA® has not been systematically studied in animals or humans for its potential for abuse, tolerance,
painful) decreased in all treatment groups from the first to the last injection (placebo: 16.7 to 12.6; 25 mg: 12.0 to 9.0; or physical dependence. Because RISPERDAL® CONSTA® is to be administered by health care professionals, the
50 mg: 18.2 to 11.8). After the sixth injection (Week 10), investigator ratings indicated that 1% of patients treated with potential for misuse or abuse by patients is low.
25 mg or 50 mg RISPERDAL® CONSTA® experienced redness, swelling, or induration at the injection site. OVERDOSAGE
Other Events Observed During the Premarketing Evaluation of RISPERDAL® CONSTA® Human Experience
During its premarketing assessment, RISPERDAL® CONSTA® was administered to 1499 patients in multiple-dose No cases of overdose were reported in premarketing studies with RISPERDAL® CONSTA® (risperidone). Because
studies. The conditions and duration of exposure to RISPERDAL® CONSTA® varied greatly, and included (in overlapping RISPERDAL® CONSTA® is to be administered by health care professionals, the potential for overdosage by patients is
categories) open-label and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, low.
fixed-dose and titration studies, and short-term and long-term exposure studies. In all studies, untoward events In premarketing experience with oral RISPERDAL® (risperidone), there were eight reports of acute RISPERDAL®
associated with this exposure were obtained by spontaneous report and were recorded by clinical investigators using overdosage, with estimated doses ranging from 20 to 300 mg and no fatalities. In general, reported signs and symptoms
terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of were those resulting from an exaggeration of the drug’s known pharmacological effects, i.e., drowsiness and sedation,
individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of tachycardia and hypotension, and extrapyramidal symptoms. One case, involving an estimated overdose of 240 mg, was
standardized event categories. associated with hyponatremia, hypokalemia, prolonged QT, and widened QRS. Another case, involving an estimated
In the listings that follow, spontaneously reported adverse events were classified using World Health Organization overdose of 36 mg, was associated with a seizure.
(WHO) preferred terms. The frequencies presented, therefore, represent the proportion of the 1499 patients exposed to Postmarketing experience with oral RISPERDAL® includes reports of acute overdose, with estimated doses of up to 360 mg.
multiple doses of RISPERDAL® CONSTA® who experienced an event of the type cited on at least one occasion while In general, the most frequently reported signs and symptoms are those resulting from an exaggeration of the drug’s
receiving RISPERDAL® CONSTA®. All reported events are included except those already listed in Table 1, those events known pharmacological effects, i.e., drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms.
for which a drug cause was remote, those event terms which were so general as to be uninformative, and those events Other adverse events reported since market introduction which were temporally (but not necessarily causally) related to
reported only once which did not have a substantial probability of being acutely life-threatening. It is important to oral RISPERDAL® overdose include torsades de pointes, prolonged QT interval, convulsions, cardiopulmonary arrest,
emphasize that, although the reported events occurred during treatment with RISPERDAL® CONSTA®, they were not and rare fatality associated with multiple drug overdose.
necessarily caused by it. Management of Overdosage
Events are further categorized by body system and listed in order of decreasing frequency according to the following In case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation.
definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic
tabulated results from the placebo-controlled trial appear in this listing); infrequent adverse events are those occurring in monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and
1/100 to 1/1000 patients; and rare events are those occurring in fewer than 1/1000 patients. quinidine carry a theoretical hazard of QT prolonging effects that might be additive to those of risperidone. Similarly, it is
Psychiatric Disorders reasonable to expect that the alpha-blocking properties of bretylium might be additive to those of risperidone, resulting
Frequent: anxiety, psychosis, depression, agitation, nervousness, paranoid reaction, delusion, apathy. Infrequent: in problematic hypotension.
anorexia, impaired concentration, impotence, emotional lability, manic reaction, decreased libido, increased appetite, There is no specific antidote to oral RISPERDAL®. Therefore, appropriate supportive measures should be instituted. The
amnesia, confusion, euphoria, depersonalization, paroniria, delirium, psychotic depression. possibility of multiple drug involvement should be considered. Hypotension and circulatory collapse should be treated
Central and Peripheral Nervous System Disorders with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine
Frequent: hypertonia, dystonia. Infrequent: dyskinesia, vertigo, leg cramps, tardive dyskinesiaa, involuntary muscle should not be used, since beta stimulation may worsen hypotension in the setting of risperidone-induced alpha
contractions, paraesthesia, abnormal gait, bradykinesia, convulsions, hypokinesia, ataxia, fecal incontinence, oculogyric blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close
crisis, tetany, apraxia, dementia, migraine. Rare: neuroleptic malignant syndrome. medical supervision and monitoring should continue until the patient recovers.
4
DOSAGE AND ADMINISTRATION Instructions for Use
For patients who have never taken oral RISPERDAL®, it is recommended to establish tolerability with oral RISPERDAL®
prior to initiating treatment with RISPERDAL® CONSTA® (risperidone).
RISPERDAL® CONSTA® should be administered every 2 weeks by deep intramuscular (IM) gluteal injection. Each
injection should be administered by a health care professional using the enclosed safety needle (see HOW SUPPLIED).
Injections should alternate between the two buttocks. Do not administer intravenously.
The recommended dose is 25 mg IM every 2 weeks. Although dose response for effectiveness has not been established
for RISPERDAL® CONSTA®, some patients not responding to 25 mg may benefit from a higher dose of 37.5 mg or 50 mg.
The maximum dose should not exceed 50 mg RISPERDAL® CONSTA® every 2 weeks. No additional benefit was
observed with dosages greater than 50 mg RISPERDAL® CONSTA®; however, a higher incidence of adverse effects was
observed.
A lower initial dose of 12.5 mg may be appropriate when clinical factors warrant dose adjustment, such as in patients
with hepatic or renal impairment, for certain drug interactions that increase risperidone plasma concentrations (see
PRECAUTIONS - Drug Interactions), or in patients who have a history of poor tolerability to psychotropic medications.
The efficacy of the 12.5 mg dose has not been investigated in clinical trials.
Oral RISPERDAL® (or another antipsychotic medication) should be given with the first injection of RISPERDAL®
CONSTA® and continued for 3 weeks (and then discontinued) to ensure that adequate therapeutic plasma concentrations
are maintained prior to the main release phase of risperidone from the injection site (see CLINICAL PHARMACOLOGY).
Upward dosage adjustment should not be made more frequently than every 4 weeks. The clinical effects of this dose RISPERDAL® CONSTA® must be reconstituted only in the diluent supplied in the dose pack, and must be administered
adjustment should not be anticipated earlier than 3 weeks after the first injection with the higher dose. with the needle supplied in the dose pack. All components are required for administration. Do not substitute any
In patients with clinical factors such as hepatic or renal impairment or certain drug interactions that increase risperidone components of the dose pack.To assure that the intended dose of risperidone is delivered, the full contents from the vial
plasma concentrations (see PRECAUTIONS – Drug Interactions), dose reduction as low as 12.5 mg may be must be administered. Administration of partial contents may not deliver the intended dose of risperidone.
appropriate. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.
Do not combine two different dosage strengths of RISPERDAL® CONSTA® in a single administration. Remove the dose pack of RISPERDAL® CONSTA® from the refrigerator and allow it to come to room temperature prior
to reconstitution.
Pediatric Use
RISPERDAL® CONSTA® has not been studied in children younger than 18 years old.
Dosage in Special Populations
For elderly patients treated with RISPERDAL® CONSTA®, the recommended dosage is 25 mg IM every 2 weeks. Oral
RISPERDAL® (or another antipsychotic medication) should be given with the first injection of RISPERDAL® CONSTA®
and should be continued for 3 weeks to ensure that adequate therapeutic plasma concentrations are maintained prior to
the main release phase of risperidone from the injection site (see CLINICAL PHARMACOLOGY).
Patients with renal or hepatic impairment should be treated with titrated doses of oral RISPERDAL® prior to initiating
treatment with RISPERDAL® CONSTA®. The recommended starting dose is 0.5 mg oral RISPERDAL® b.i.d. during the 1. Flip off the plastic colored cap from the vial.
first week, which can be increased to 1 mg b.i.d. or 2 mg once daily during the second week. If a total daily dose of at
least 2 mg oral RISPERDAL® is well tolerated, an injection of 25 mg RISPERDAL® CONSTA® can be administered every
2 weeks. Alternatively, a starting dose of RISPERDAL® CONSTA® of 12.5 mg may be appropriate. The efficacy of the
12.5 mg dose has not been investigated in clinical trials.
Oral supplementation should be continued for 3 weeks after the first injection until the main release of risperidone from
the injection site has begun. In some patients, slower titration may be medically appropriate.
Patients with renal impairment may have less ability to eliminate risperidone than normal adults. Patients with impaired
hepatic function may have an increase in the free fraction of the risperidone, possibly resulting in an enhanced effect
(see CLINICAL PHARMACOLOGY). Elderly patients and patients with a predisposition to hypotensive reactions or for 2. Peel back the blister pouch and remove the SmartSite®
whom such reactions would pose a particular risk should be instructed in nonpharmacologic interventions that help to Needle-Free Vial Access Device by holding the white luer
reduce the occurrence of orthostatic hypotension (e.g., sitting on the edge of the bed for several minutes before cap. Do not touch the spike tip of the access device at any
attempting to stand in the morning and slowly rising from a seated position). These patients should avoid sodium time.
depletion or dehydration, and circumstances that accentuate hypotension (alcohol intake, high ambient temperature,
etc.). Monitoring of orthostatic vital signs should be considered (see PRECAUTIONS).
Maintenance Therapy
Although no controlled studies have been conducted to answer the question of how long patients should be treated with
RISPERDAL® CONSTA®, oral risperidone has been shown to be effective in delaying time to relapse in longer-term use.
It is recommended that responding patients be continued on treatment with RISPERDAL® CONSTA® at the lowest dose
needed. Patients should be periodically reassessed to determine the need for continued treatment.
Reinitiation of Treatment in Patients Previously Discontinued
There are no data to specifically address reinitiation of treatment. When restarting patients who have had an interval off
treatment with RISPERDAL® CONSTA®, supplementation with oral RISPERDAL® (or another antipsychotic medication)
should be administered.
Switching from Other Antipsychotics
There are no systematically collected data to specifically address switching schizophrenic patients from other
antipsychotics to RISPERDAL® CONSTA®, or concerning concomitant administration with other antipsychotics. Previous
antipsychotics should be continued for 3 weeks after the first injection of RISPERDAL® CONSTA® to ensure that
therapeutic concentrations are maintained until the main release phase of risperidone from the injection site has begun
(see CLINICAL PHARMACOLOGY). For schizophrenic patients who have never taken oral RISPERDAL®, it is
recommended to establish tolerability with oral RISPERDAL® prior to initiating treatment with RISPERDAL® CONSTA®.
As recommended with other antipsychotic medications, the need for continuing existing EPS medication should be 3. Place vial on a hard surface. Press the spike tip of the
re-evaluated periodically. SmartSite® Access Device through the center of the
vial’s rubber stopper until the device securely snaps
Co-Administration of RISPERDAL® CONSTA® with Certain Other Medications into place.
Co-administration of carbamazepine and other CYP 3A4 enzyme inducers (e.g., phenytoin, rifampin, phenobarbital) with
risperidone would be expected to cause decreases in the plasma concentrations of active moiety (the sum of
risperidone and 9–hydroxyrisperidone), which could lead to decreased efficacy of RISPERDAL® CONSTA® treatment.
The dose of risperidone needs to be titrated accordingly for patients receiving these enzyme inducers, especially during
initiation or discontinuation of therapy with these inducers (see CLINICAL PHARMACOLOGY and PRECAUTIONS). At
the initiation of therapy with carbamazepine or other known CYP 3A4 hepatic enzyme inducers, patients should be
closely monitored during the first 4-8 weeks, since the dose of RISPERDAL® CONSTA® may need to be adjusted. A
dose increase, or additional oral RISPERDAL®, may need to be considered. On discontinuation of carbamazepine or
other CYP 3A4 hepatic enzyme inducers, the dosage of RISPERDAL® CONSTA® should be re-evaluated and, if
necessary, decreased. Patients may be placed on a lower dose of RISPERDAL® CONSTA® between 2 to 4 weeks
before the planned discontinuation of carbamazepine or other CYP 3A4 enzyme inducers to adjust for the expected
increase in plasma concentrations of risperidone plus 9–hydroxyrisperidone. For patients treated with the recommended
dose of 25 mg RISPERDAL® CONSTA® and discontinuing from carbamazepine or other CYP 3A4 enzyme inducers, it is
recommended to continue treatment with the 25-mg dose unless clinical judgment necessitates lowering the 4. Swab the syringe connection point (blue circle) of the
RISPERDAL® CONSTA® dose to 12.5 mg or necessitates interruption of RISPERDAL® CONSTA® treatment. The efficacy SmartSite® Access Device with preferred antiseptic
of the 12.5 mg dose has not been investigated in clinical trials. prior to attaching the syringe to the SmartSite® Access
Fluoxetine and paroxetine, CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone Device.
2.5-2.8 fold and 3-9 fold respectively. Fluoxetine did not affect the plasma concentration of 9–hydroxyrisperidone.
Paroxetine lowered the concentration of 9- hydroxyrisperidone by about 10%. The dose of risperidone needs to be
titrated accordingly when fluoxetine or paroxetine is co-administered. When either concomitant fluoxetine or paroxetine is
initiated or discontinued, the physician should re-evaluate the dose of RISPERDAL® CONSTA®. When initiation of
fluoxetine or paroxetine is considered, patients may be placed on a lower dose of RISPERDAL® CONSTA® between 2 to
4 weeks before the planned start of fluoxetine or paroxetine therapy to adjust for the expected increase in plasma
concentrations of risperidone. When fluoxetine or paroxetine is initiated in patients receiving the recommended dose of
25 mg RISPERDAL® CONSTA®, it is recommended to continue treatment with the 25 mg dose unless clinical judgment
necessitates lowering the RISPERDAL® CONSTA® dose to 12.5 mg or necessitates interruption of RISPERDAL®
CONSTA® treatment. When RISPERDAL® CONSTA® is initiated in patients already receiving fluoxetine or paroxetine, a
starting dose of 12.5 mg can be considered. The efficacy of the 12.5 mg dose has not been investigated in clinical trials.
The effects of discontinuation of concomitant fluoxetine or paroxetine therapy on the pharmacokinetics of risperidone
and 9–hydroxyrisperidone have not been studied.
5.Twist off the white cap from the pre-filled syringe and
remove together with the rubber tip cap inside.
5
13. Attach the luer connection of the Needle-Pro® device to the syringe with an easy clockwise twisting motion. Seat the
needle firmly on the Needle-Pro® device with a push and clockwise twist.
14. If 2 minutes pass before injection, re-suspend by shaking vigorously.
6. Press the syringe tip into the blue circle of the
SmartSite® Access Device and Twist in a clockwise
motion to ensure that the syringe is securely attached to
the white luer cap of the access device. Keep the
syringe and SmartSite® Access Device aligned, and hold
the skirt of the access device during attachment to
prevent spinning. 15. Pull sheath away from the needle. Do not twist sheath,
as needle may be loosened from Needle-Pro® device.
Tap the syringe gently to make any air bubbles rise to
the top. De-aerate syringe by moving plunger rod
carefully forward, with needle in an upward position.
Inject entire contents intramuscularly (IM) into the
upper-outer quadrant of the gluteal area within 2
minutes to avoid settling. DO NOT ADMINISTER
INTRAVENOUSLY.
WARNING: To avoid a needle stick injury with a contaminated needle, do not:
7. Inject the entire contents of the syringe containing the
diluent into the vial. • intentionally disengage the Needle-Pro® device
• attempt to straighten the needle or engage Needle-Pro® device if the needle is bent or damaged
• mishandle the needle protection device that could lead to protrusion of the needle from it
16. After injection is complete, use only one hand and
tabletop or other hard surface to snap needle into the
orange needle protector device before discarding.
Discard needle appropriately.
8. Shake the vial vigorously while holding the plunger rod
down with the thumb for a minimum of 10 seconds to
ensure a homogeneous suspension. When properly
mixed, the suspension appears uniform, thick, and milky
in color. The particles will be visible in liquid, but no dry
particles remain.
Upon suspension in the diluent, it is recommended to use RISPERDAL® CONSTA® immediately. RISPERDAL®
CONSTA® must be used within 6 hours of suspension. Resuspension of RISPERDAL® CONSTA® will be necessary prior
to administration, as settling will occur over time once the product is in suspension. Keeping the vial upright, shake
vigorously back and forth for as long as it takes to resuspend the microspheres. Once in suspension, the product should
not be exposed to temperatures above 77°F (25°C).
9. Do not store the vial after reconstitution or the suspension may settle. If 2 minutes pass before injection, re-suspend
by shaking vigorously. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration,
whenever solution and container permit.
HOW SUPPLIED
RISPERDAL® CONSTA® (risperidone) is available in dosage strengths of 12.5, 25, 37.5, or 50 mg risperidone. It is
provided as a dose pack, consisting of a vial containing the risperidone microspheres, a pre-filled syringe containing 2 mL
of diluent for RISPERDAL® CONSTA®, a SmartSite® Needle-Free Vial Access Device, and one Needle-Pro® safety needle
for intramuscular injection (20 G TW needle with needle protection device).
12.5-mg vial/kit (NDC 50458-309-11): 12.5 mg of a white to off-white powder provided in a vial with a violet flip-off cap
(NDC 50458-309-01).
10. Invert the vial completely and slowly withdraw the 25-mg vial/kit (NDC 50458-306-11): 25 mg of a white to off-white powder provided in a vial with a pink flip-off cap
suspension from the vial. Tear section of the vial label (NDC 50458-306-01).
at the perforation and apply detached label to syringe 37.5-mg vial/kit (NDC 50458-307-11): 37.5 mg of a white to off-white powder provided in a vial with a green flip-off cap
for identification purposes. (NDC 50458-307-01).
50-mg vial/kit (NDC 50458-308-11): 50 mg of a white to off-white powder provided in a vial with a blue flip-off cap
(NDC 50458-308-01).
Storage and Handling
The entire dose pack should be stored in the refrigerator (36°- 46°F; 2°- 8°C) and protected from light.
If refrigeration is unavailable, RISPERDAL® CONSTA® can be stored at temperatures not exceeding 77°F (25°C) for no
more than 7 days prior to administration. Do not expose unrefrigerated product to temperatures above 77°F (25°C).
Keep out of reach of children.
7519510
Revised September 2007
©Janssen 2003
Risperidone is manufactured by: Diluent is manufactured by:
11. Unscrew the syringe from the SmartSite® access Janssen Pharmaceutical Ltd. Vetter Pharma Fertigung GmbH & Co. KG
device and discard both the vial and access device Wallingstown, Little Island, County Cork, Ireland Ravensburg or Langenargen, Germany or
appropriately. Cilag, AG
Microspheres are manufactured by: Schaffhausen, Switzerland or
Alkermes Controlled Therapeutics II Ortho Biotech Products, L.P.
Wilmington, Ohio Raritan, New Jersey
RISPERDAL® CONSTA® is distributed by:
Janssen, L.P.
Titusville, NJ 08560
12. Peel the blister pouch of the Needle-Pro® device open
halfway. Grasp sheath using the plastic peel pouch.
6
